Scarica l'app Stockscreener
53.27
0.20%
-0.245
Bright Minds Biosciences Inc Borsa (DRUG) Ultime notizie
Bright Minds Biosciences Inc. (DRUG) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Bright Minds Biosciences (NASDAQ:DRUG) Trading Down 6.9%Here's What Happened - MarketBeat
Bright Minds Biosciences Slides Under Pressure: Pre-Revenue Cash Burn and Insider Selling Weigh on Clinical-Stage Sentiment - kalkine.ca
Earnings Calendar for: - finance.yahoo.com
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Stock Rating Lowered by Zacks Research - MarketBeat
WHY Goldsky Resources (TSXV:GSKR), Dexterra Group (TSX:DXT), Bright Minds Biosciences (CN:DRUG), Magna Mining (TSX:NICU) and ADENTRA (TSX:ADEN) Could Put the TSX SmallCap Watchlist in Focus in September 2026 - kalkine.ca
Trading the Move, Not the Narrative: (DRUG) Edition - Stock Traders Daily
Top 10 Best Biotech Companies In Canada 2026 - Nubia Magazine!
Bright Minds Biosciences to Present at Upcoming Conferences - The Manila Times
Bright Minds Biosciences Stock Slides 4.82% as Biotech Volatility Bites: Is More Downside Pressure Ahead for CN:DRUG? - kalkine.ca
Bright Minds Biosciences Faces Fresh Pressure as Clinical Execution Risk Weighs on Sentiment - kalkine.ca
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Down 5.2%Time to Sell? - MarketBeat
Braidwell LP Decreases Stock Holdings in Bright Minds Biosciences Inc. $DRUG - MarketBeat
Bright Minds Biosciences Stock Falls 3.06%: CN:DRUG Faces Correction Pressure as Clinical and Valuation Risks Test Sentiment - kalkine.ca
Bright Minds Biosciences Inc (DRUG) Peer Comparison – Compare with Others - Value Research
Aptose Biosciences Inc. (APTO) Peer Comparison – Compare with Others - Value Research
DRUG: Bright Minds Biosciences Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Bright Minds Biosciences Inc (DRUG) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Bright Minds Biosciences Stock Falls 3.85%: Is CN:DRUG Facing Renewed Biotech Volatility as Clinical Risks Remain? - kalkine.ca
Bright Minds Biosciences Stock Faces Fresh Pressure as Biotech Sentiment Weakens - kalkine.ca
What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now? - Eastern Progress
13% Of This Bright Minds Biosciences Insider's Holdings Were Sold - simplywall.st
Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High? - finance.yahoo.com
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Wall Street Zen Upgrades Bright Minds Biosciences (NASDAQ:DRUG) to Hold - MarketBeat
Bright Minds Biosciences Stock Falls 4.60% as Investors Weigh BMB-101 Clinical Progress Against Biotech Development Risk - kalkine.ca
What is HC Wainwright's Forecast for DRUG FY2026 Earnings? - MarketBeat
Bright Minds Biosciences Slides as Biotech Volatility Returns — What Could Wake the Stock Up? - kalkine.ca
Bright Minds Biosciences Stock Faces Fresh Pressure — Can Clinical Momentum Offset Rising Correction Risk? - kalkine.ca
Psychedelic: Enveric, Helus, Bright Minds report earnings results - TipRanks
H.C. Wainwright reiterates Bright Minds stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Bright Minds stock rating at buy - Investing.com
Bright Minds Biosciences (NASDAQ:DRUG) Earns "Buy" Rating from HC Wainwright - MarketBeat
Bright Minds Biosciences Stock: An Epilepsy Story Keeps Drawing Biotech Money - kalkine.ca
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 5.9%Should You Buy? - MarketBeat
BTIG Research Reiterates "Buy" Rating for Bright Minds Biosciences (NASDAQ:DRUG) - MarketBeat
TD Cowen Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating - Moomoo
Bright Minds Biosciences (DRUG) Earnings Date and Reports 2026 $DRUG - MarketBeat
Liquidity Mapping Around (DRUG) Price Events - Stock Traders Daily
Bright Minds Biosciences (NASDAQ:DRUG) Issues Quarterly Earnings Results - MarketBeat
Bright Minds (DRUG) reports Phase 2 seizure gains in treatment‑resistant epilepsy - Stock Titan
Bright Minds Biosciences (DRUG): Cormorant Asset Management reports 9.17% ownership stake - Stock Titan
Bright Minds Biosciences (DRUG) Slips to $78.00 as Traders Eye Support at $74.1Chart Pattern Alerts - vinanet.vn
Can Bright Minds (TSX:DRUG) Keep Biotech Momentum Going? - Kalkine Media
Adage Capital (DRUG) discloses 3.41% Bright Minds Biosciences stake in latest holding - Stock Titan
Bright Minds Biosciences Inc. expected to post a loss of C$1.76 a shareEarnings Preview - TradingView
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet - finance.yahoo.com
Bright Minds Biosciences Inc (CN:DRUG) Shares Under Pressure as Biotech Sentiment Weakens and Development Risks Increase - kalkine.ca
Bright Minds: BMB-101 Takes Center Stage Ahead Of Phase 3 Pivotal Trials (NASDAQ:DRUG) - Seeking Alpha
Bright Minds Biosciences (CN:DRUG): The Ticker Everyone's Talking About After a US$175M Raise and a Seizure Data Bombshell - kalkine.ca
Bright Minds Biosciences Inc (CN:DRUG) Jumps 4.05%: neuroscience biotech's Canadian line rose to C$114 on almost no volume, a thin-trading blip rather than - kalkine.ca
Bright Minds Biosciences (DRUG) to Post Quarterly Earnings on Thursday - MarketBeat
Why (DRUG) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Bright Minds' BMB-101 Cuts Absence Seizures 73% in EEG-Confirmed Phase 2 Signal, But Small Open-Label Study Leaves Questions - kalkine.ca
Perceptive Advisors LLC Sells 71,746 Shares of Bright Minds Biosciences Inc. $DRUG - MarketBeat
Janus Henderson Group PLC Raises Holdings in Bright Minds Biosciences Inc. $DRUG - MarketBeat
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
ADAR1 Capital Management LLC Has $2.47 Million Stock Position in Bright Minds Biosciences Inc. $DRUG - MarketBeat
Bright Minds Biosciences Inc (DRUG) Cash Flow - TradingKey
40,000 Shares in Bright Minds Biosciences Inc. $DRUG Acquired by Orbimed Advisors LLC - MarketBeat
Bright Minds Biosciences Inc (DRUG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
4.04%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):